

anti-Human Etokimab Monoclonal Antibody | anti-IL33 antibody

Research Grade Etokimab

CATALOG #
AAA119960

REACTIVITY
Human


PRODUCT SYNONYMS

Etokimab; Monoclonal Antibody; Research Grade Etokimab; ANB020; NF-HEV; IL-1F11; C9orf26; IL-33; Interleukin-1 family member 11; IL33; Nuclear factor from high endothelial venules; NFHEV; Interleukin-33; IL1F11; anti-IL33 antibody

PRODUCT SPECIFICATIONS

Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1-kappa
Purity/Purification	>95%; Protein A or G purified from cell culture supernatant.
Form/Format	Liquid. PBS buffer, pH7.4
Concentration	0.65 mg/ml (varies by lot)
Expression System	Mammalian cells
Host Species	Humanized
CAS	2022981-44-6
Preparation and Storage	Store at -20 degree C 12 months. Store at -80 degree C long term. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

IMAGES



SDS-PAGE

SDS PAGE for Etokimab

ADDITIONAL INFORMATION

Related Product Information for anti-IL33 antibody	ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobulin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.
Product Categories/Family for anti-IL33 antibody	Research Biosimilar
References	Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis, PMID: 34213742 Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy, PMID: 31723064 Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis, PMID: 31645451 Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis, PMID: 32507066 The use of biologics in food allergy, PMID: 33966304

NCBI AND UNIPROT INFORMATION

NCBI GI #	314122337
NCBI GeneID	90865
NCBI Accession #	NP_001186570.1
NCBI GenBank Nucleotide #	NM_001199641.1
UniProt Accession #	O95760; Q2YEJ5; B4DJ35; B4E1Q9; D3DRI5; E7EAX4
NCBI Official Full Name	interleukin-33 isoform 3
NCBI Official Synonym Full Names	interleukin 33
NCBI Official Symbol	IL33
NCBI Official Synonym Symbols	DVS27; IL1F11; NF-HEV; NFEHEV; C9orf26; RP11-575C20.2
NCBI Protein Information	interleukin-33; IL-33; IL-1F11; DVS27-related protein; interleukin-1 family member 11; nuclear factor for high endothelial venules; nuclear factor from high endothelial venules
UniProt Protein Name	Interleukin-33
UniProt Gene Name	IL33
UniProt Synonym Gene Names	C9orf26; IL1F11; NFHEV; IL-33; IL-1F11; NF-HEV
UniProt Entry Name	IL33_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/monoclonal/etokimab-antibody-elisa/119960>